Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.4%

1 terminated out of 41 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

5%

2 trials in Phase 3/4

Results Transparency

20%

2 of 10 completed with results

Key Signals

2 with results91% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (14)
Early P 1 (1)
P 1 (7)
P 2 (4)
P 3 (2)

Trial Status

Not Yet Recruiting15
Completed10
Recruiting8
Enrolling By Invitation3
Active Not Recruiting2
Withdrawn1

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (41)

Showing 20 of 20 trials
NCT07564700Not ApplicableNot Yet RecruitingPrimary

A Study Testing Whether Low-Dose Radiation Could Help the Immune System and Possibly Improve Early-Onset Alzheimer's Disease.

NCT07554872Phase 1Not Yet RecruitingPrimary

Study of Neural Stem Cell-Derived Exosomes in Moderate-to-Severe Early-Onset Alzheimer's Disease

NCT07558785Not ApplicableEnrolling By Invitation

Telemedicine Self-examination of Speech and Memory for Rapid Detection of Cognitive Impairments Using Machine Learning Methods

NCT07526480Not ApplicableNot Yet RecruitingPrimary

Improving Dementia Care in Primary Practice

NCT07505095Not Yet RecruitingPrimary

Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice

NCT07127510RecruitingPrimary

Brain NAD in Alzheimer's Disease

NCT07180147Active Not RecruitingPrimary

Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)

NCT07431255Not Yet RecruitingPrimary

Generation of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease

NCT06831812Phase 1Completed

Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine

NCT07422038Not Yet RecruitingPrimary

BioMIND (Biomarkers for the Molecular Identification of Neurodegenerative Dementia) - Improving Access to Alzheimer's Disease Diagnostics: A Pragmatic System Level Intervention

NCT07385937Not ApplicableNot Yet RecruitingPrimary

Effectiveness of Genistein in Mild Cognitive Impairment

NCT03402919Recruiting

Comprehensive Assessment of Neurodegeneration and Dementia

NCT07234695Phase 3Recruiting

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

NCT07099001Not ApplicableCompletedPrimary

Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay

NCT07213349Phase 2RecruitingPrimary

Daridorexant for Alzheimer Disease Prevention

NCT06797817Phase 3Not Yet RecruitingPrimary

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain

NCT07287852Phase 2Enrolling By InvitationPrimary

A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI

NCT07251738Not Yet RecruitingPrimary

Understanding the Lived Experience and Bereavement of Caregivers of People With Alzheimer's Disease

NCT07237958Not ApplicableCompletedPrimary

Effects on the Olfactory Epithelium and the Olfactory Nerve From Exposure to Diesel Exhaust

NCT07238049Enrolling By InvitationPrimary

REAl World Dementia OUTcomes: Observational Study

Scroll to load more

Research Network

Activity Timeline